Passage BIO, Inc. (PASG) · Nov 18, 2026 · Delisting

Passage Bio delisting notice exposes $50,000 equity gap

Nasdaq deficiency — $50,000 equity vs $2.5 million requirement

Passage Bio received a Nasdaq delisting notice after its equity fell to $50,000. The Remix merger is now the company’s path back to compliance.

Passage Bio is a cash-constrained shell transitioning into Remix Therapeutics. The company has been winding down its gene-therapy programs and relying on the planned Remix merger as its strategic reset; its September 30, 2026 filing said its ability to continue as a going concern depended on completing that merger or obtaining substantial additional funding. Passage shareholders approved the merger-related proposals on November 5, 2026, so the transaction was already the expected route forward before this filing.

The new information is a formal Nasdaq compliance failure, not a surprise deterioration in the operating business. Nasdaq requires at least $2.5 million of stockholders’ equity, while Passage reported only $50,000 at September 30, leaving it far below the threshold and without the alternative market-value or income qualification. 〔0〕

MetricReportedRequirement
Stockholders’ equity (Item 3.01)$50,000$2,500,000

The immediate consequence is limited, but the merger is now more operationally important. The notice does not suspend trading, and the company says its shares will continue trading on Nasdaq for now. 〔1〕 But the planned merger—and Nasdaq’s approval of the combined company’s listing—has become the practical bridge between the current balance sheet and continued exchange access. Passage says it expects to regain compliance once the deal closes, but that outcome remains conditional rather than completed. 〔2〕

Bottom line: This is a modestly negative filing because it formalizes a severe capital deficiency, while leaving trading intact and preserving the already-public merger solution. It matters mainly by adding execution risk to a transaction the company already needs to complete.

What to watch next

Merger closing and Nasdaq listing approval

Original filing on SEC EDGAR

More Passage BIO, Inc. news

Passage Bio delisting notice exposes $50,000 equity gap | PASG Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.